Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E K Rowinsky

Showing results (151-160 of 159) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 159 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemiaS D Gore, L J Weng, S Zhai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxelM Hidalgo, C Aylesworth, L A Hammond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 1999
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignanciesC D Britten, E K Rowinsky, S D Baker, et al.
British Journal of Cancer|September 1, 2011
Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancerA C Mita, K Papadopoulos, M J A de Jonge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 1999
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumorsS G Diab, S D Baker, A Joshi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2000
Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignanciesM Hidalgo, M A Villalona-Calero, S G Eckhardt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2000
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignanciesS G Eckhardt, S D Baker, C D Britten, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeksS G Eckhardt, S D Baker, J R Eckardt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumorsS G Eckhardt, J Rizzo, K R Sweeney, et al.
Pageof 16

Showing results (151-160 of 159) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 159 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemiaS D Gore, L J Weng, S Zhai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxelM Hidalgo, C Aylesworth, L A Hammond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 1999
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignanciesC D Britten, E K Rowinsky, S D Baker, et al.
British Journal of Cancer|September 1, 2011
Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancerA C Mita, K Papadopoulos, M J A de Jonge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 1999
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumorsS G Diab, S D Baker, A Joshi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2000
Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignanciesM Hidalgo, M A Villalona-Calero, S G Eckhardt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2000
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignanciesS G Eckhardt, S D Baker, C D Britten, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeksS G Eckhardt, S D Baker, J R Eckardt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumorsS G Eckhardt, J Rizzo, K R Sweeney, et al.
Pageof 16